- Home
- ANAB vs AZUL Comparison
ANAB vs AZUL Comparison
Compare ANAB & AZUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- AZUL
- Stock Information
- Founded
- ANAB 2005
- AZUL 2008
- Country
- ANAB United States
- AZUL Brazil
- Employees
- ANAB N/A
- AZUL N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- AZUL Air Freight/Delivery Services
- Sector
- ANAB Health Care
- AZUL Consumer Discretionary
- Exchange
- ANAB Nasdaq
- AZUL Nasdaq
- Market Cap
- ANAB 681.9M
- AZUL 337.4M
- IPO Year
- ANAB 2017
- AZUL 2017
- Fundamental
- Price
- ANAB $35.90
- AZUL $2.32
- Analyst Decision
- ANAB Buy
- AZUL Buy
- Analyst Count
- ANAB 10
- AZUL 8
- Target Price
- ANAB $50.30
- AZUL $8.23
- AVG Volume (30 Days)
- ANAB 357.1K
- AZUL 3.4M
- Earning Date
- ANAB 10-31-2024
- AZUL 08-12-2024
- Dividend Yield
- ANAB N/A
- AZUL N/A
- EPS Growth
- ANAB N/A
- AZUL N/A
- EPS
- ANAB N/A
- AZUL N/A
- Revenue
- ANAB $30,473,000.00
- AZUL $3,363,545,458.00
- Revenue This Year
- ANAB $90.79
- AZUL N/A
- Revenue Next Year
- ANAB N/A
- AZUL $11.85
- P/E Ratio
- ANAB N/A
- AZUL N/A
- Revenue Growth
- ANAB 135.59
- AZUL 6.32
- 52 Week Low
- ANAB $13.36
- AZUL $2.25
- 52 Week High
- ANAB $41.31
- AZUL $11.26
- Technical
- Relative Strength Index (RSI)
- ANAB 52.35
- AZUL 21.97
- Support Level
- ANAB $34.91
- AZUL $2.25
- Resistance Level
- ANAB $37.55
- AZUL $2.70
- Average True Range (ATR)
- ANAB 1.73
- AZUL 0.27
- MACD
- ANAB -0.22
- AZUL -0.17
- Stochastic Oscillator
- ANAB 47.50
- AZUL 3.04
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About AZUL Azul S.A. (each representing three preferred shares)
Azul SA is involved in the operation of regular and non-regular airline passenger services, cargo or mail, passenger charter, provision of maintenance and hangarage services for aircraft, engines, parts and pieces, aircraft acquisition and lease, development of frequent-flyer programs, development of related activities and equity holding in other companies. The Company considers that it has a single reportable segment which is air transport.